CDNA vs DCTH: fair value comparison
CareDx, Inc. and Delcath Systems, Inc. · Updated 2026-10-19
DCTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CDNA currently ranks higher by quality score.
| CDNA | DCTH | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $64.00 | $14.08 |
| 12-month range | $14.28–$69.85 | $8.19–$17.36 |
| Rank by discount to fair value | #94 of 108 Healthcare | — |
| Rank by quality score | #1 of 301 Healthcare | #2 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: CDNA fair value analysis · DCTH fair value analysis